clinical trial · NCT07422389

BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

Limbal Stem Cell Deficiency (LSCD)BRM421 Ophthalmic Solution, 0.06%

brief summary

The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests

started

—

primary completion

—

completion

—

last updated

Feb 20, 2026

official title

Intermediate-Size Patient Population Use of BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol